APA (7th ed.) Citation

HF, T., DH, E., R, S., D, M., M, B., H, R., . . . OM, E. (2022). Outcome of docetaxel in treatment of metastatic hormone-sensitive prostate cancer and correlation with hemoglobin, albumin, lymphocyte and platelets score. Contemporary oncology (Poznan, Poland), 26(3), 196. https://doi.org/10.5114/wo.2022.120592

Chicago Style (17th ed.) Citation

HF, Taha, Elsayed DH, Salem R, Mandour D, Bayomy M, Rashed H, Kamel M, Elderey M, and Elfarargy OM. "Outcome of Docetaxel in Treatment of Metastatic Hormone-sensitive Prostate Cancer and Correlation with Hemoglobin, Albumin, Lymphocyte and Platelets Score." Contemporary Oncology (Poznan, Poland) 26, no. 3 (2022): 196. https://doi.org/10.5114/wo.2022.120592.

MLA (9th ed.) Citation

HF, Taha, et al. "Outcome of Docetaxel in Treatment of Metastatic Hormone-sensitive Prostate Cancer and Correlation with Hemoglobin, Albumin, Lymphocyte and Platelets Score." Contemporary Oncology (Poznan, Poland), vol. 26, no. 3, 2022, p. 196, https://doi.org/10.5114/wo.2022.120592.